IR Department
  • About Us
    • Overview
    • Our Team
    • Our ESG Position
    • Careers
  • Services
    • What We Do
    • Investor Relations
    • IPO Readiness
    • Media Relations
    • Issues and Crisis Communications
    • Digital Content & Social Media Activation
    • Marketing and Brand Campaigns
    • Video Production
    • ESG
    • ESG Competent Boards Masterclass
  • News & events
    • Blog
  • Contact
    • Contact Us
    • Email Alerts
IR Department Newsletter - September 2022
News & events >
  • Blog

Recent Posts

  • HealthInvest April 2025 recap: bringing life sciences to the forefront
  • Upcoming: HealthInvest April 2025
  • Equity Insights: December Issue
  • Navigating AGM Season: Insights from Jane Lowe
  • 3 ways new ESG management and auditing standards could affect all Australian listed companies

Archives

  • April 2025
  • March 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • May 2024
  • December 2023
  • October 2023
  • July 2023
  • March 2023
  • February 2023
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • March 2022
  • February 2022

Categories

  • AGMs
  • Crisis communications
  • Equity Insights
  • ESG
  • Investor relations
  • Newsletter March 2022
  • Newsletter Sept 2022
  • Uncategorized

IR Department Newsletter – September 2022

IRD nl
August 31st, 2022

IR Department client media highlights

Read More
PeterDevineinterview20220815_100255MeetingRecording00_00_46_15Still001
August 31st, 2022

Interview with Peter Devine, CEO of Uniseed

Read More
XPONnl
August 29th, 2022

XPON CEO Matt Forman discusses Wondaris and how it integrates with Google

Read More
Kazianl
August 29th, 2022

Kazia Therapeutics CEO Dr James Garner talks with SmallCaps about what's on the horizon

Read More
Mathiasnl
August 29th, 2022

Interview with Assoc.Prof. Mathias Francois of Gertrude Biomedical

Read More
Tertianl
August 29th, 2022

HaemaLogiX's Tertia Dex explains the KappaMab antibody

Read More
Danielnl
August 29th, 2022

Race Oncology CSO Dr Daniel Tillett discusses the bright future for Zantrene

Read More
David F nl
August 29th, 2022

Mosquito-borne diseases in Australia - an interview with Dr David Foster, CEO of Island Pharmaceuticals

Read More
1AD nl
July 4th, 2022

Podcast - IR Department talks with AdAlta CEO & MD, Dr Tim Oldham

Read More
  • 1


IR Department acknowledge the Traditional Owners of the land on which it operates and pays respect to Elders past, present and emerging.

Subscribe

Which of the following group do you best fit?

 
By subscribing you agree to with our Privacy Policy

Site Map Privacy Search
IR Department . All rights reserved. - Site by